Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15865430rdf:typepubmed:Citationlld:pubmed
pubmed-article:15865430lifeskim:mentionsumls-concept:C0002318lld:lifeskim
pubmed-article:15865430lifeskim:mentionsumls-concept:C1705425lld:lifeskim
pubmed-article:15865430lifeskim:mentionsumls-concept:C0181496lld:lifeskim
pubmed-article:15865430lifeskim:mentionsumls-concept:C0243071lld:lifeskim
pubmed-article:15865430lifeskim:mentionsumls-concept:C1171720lld:lifeskim
pubmed-article:15865430lifeskim:mentionsumls-concept:C1522485lld:lifeskim
pubmed-article:15865430pubmed:issue18lld:pubmed
pubmed-article:15865430pubmed:dateCreated2005-5-3lld:pubmed
pubmed-article:15865430pubmed:abstractTextA synthetic analogue of the tripeptide hemiasterlin, designated HTI-286, depolymerizes microtubules, is a poor substrate for P-glycoprotein, and inhibits the growth of paclitaxel-resistant tumors in xenograft models. Two radiolabeled photoaffinity analogues of HTI-286, designated 4-benzoyl-N,beta,beta-trimethyl-l-phenylalanyl-N(1)-[(1S,2E)-3-carboxy-1-isopropylbut-2-enyl]-N(1),3-dimethyl-l-valinamide (probe 1) and N,beta,beta-trimethyl-l-phenylalanyl-4-benzoyl-N-[(1S,2E)-3-carboxy-1-isopropyl-2-butenyl]-N,beta,beta-trimethyl-l-phenylalaninamide (probe 2), were made to help identify HTI-286 binding sites in tubulin. HTI-286, probe 1, and probe 2 had similar affinities for purified tubulin [apparent K(D(app)) = 0.2-1.1 microM], inhibited polymerization of purified tubulin approximately 80%, and were potent inhibitors of cell growth (IC(50) = 1.0-22 nM). Both radiolabeled probes labeled exclusively alpha-tubulin. Labeling by [(3)H]probe 1 was inhibited by probe 1, HTI-286, vinblastine, or dolastatin 10 (another peptide antimitotic agent that depolymerizes microtubules) but was either unaffected or enhanced (at certain temperatures) by colchicine or paclitaxel. [(3)H]Probe 1 also labeled exclusively tubulin in cytosolic extracts of whole cells. The major, if not exclusive, contact site for probe 1 was mapped to residues 314-339 of alpha-tubulin and corresponds to the sheet 8 and helix 10 region. This region is known to (1) have longitudinal interactions with beta-tubulin across the interdimer interface, (2) have lateral interactions with adjacent protofilaments, and (3) contact the N-terminal region of stathmin, a protein that induces depolymerization of tubulin. Binding of probe 1 to this region may alter the conformation of tubulin outside the labeling domain, since enzymatic removal of the C-terminus of only alpha-tubulin by subtilisin after, but not before, photolabeling is blocked by probe 1. These results suggest that hemiasterlin is in close contact with alpha-tubulin and may span the interdimer interface so that it contacts the vinblastine- and dolastatin 10-binding sites believed to be in beta-tubulin. In addition, we speculate that antimitotic peptides mimic the interaction of stathmin with tubulin.lld:pubmed
pubmed-article:15865430pubmed:languageenglld:pubmed
pubmed-article:15865430pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:citationSubsetIMlld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15865430pubmed:statusMEDLINElld:pubmed
pubmed-article:15865430pubmed:monthMaylld:pubmed
pubmed-article:15865430pubmed:issn0006-2960lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:NunesMariaMlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:Krishnamurthy...lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:QiuYongchangYlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:GreenbergerLe...lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:Ayral-Kaloust...lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:LoganzoFrankFlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:BeyerCarlClld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:MustoSylviaSlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:HariMalathiMlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:ZaskArieAlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:WootersJoseph...lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:ShiCelineClld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:MayMichael...lld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:KaplanJoshuaJlld:pubmed
pubmed-article:15865430pubmed:authorpubmed-author:MinnickAlbert...lld:pubmed
pubmed-article:15865430pubmed:issnTypePrintlld:pubmed
pubmed-article:15865430pubmed:day10lld:pubmed
pubmed-article:15865430pubmed:volume44lld:pubmed
pubmed-article:15865430pubmed:ownerNLMlld:pubmed
pubmed-article:15865430pubmed:authorsCompleteYlld:pubmed
pubmed-article:15865430pubmed:pagination6844-57lld:pubmed
pubmed-article:15865430pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:meshHeadingpubmed-meshheading:15865430...lld:pubmed
pubmed-article:15865430pubmed:year2005lld:pubmed
pubmed-article:15865430pubmed:articleTitleTwo photoaffinity analogues of the tripeptide, hemiasterlin, exclusively label alpha-tubulin.lld:pubmed
pubmed-article:15865430pubmed:affiliationOncology Research, Chemical and Screening Sciences, Radiosynthesis Group, and Bioorganic Enzymology, Wyeth Research, 401 North Middletown Road, Pearl River, New York 10965, USA. nunesm@wyeth.comlld:pubmed
pubmed-article:15865430pubmed:publicationTypeJournal Articlelld:pubmed